HepatologyNews.net

Hepatology Xagena

Real-world effectiveness data are needed to inform hepatitis C virus ( HCV ) treatment decisions. The uptake of Ledipasvir and Sofosbuvir ( LDV/SOF; Harvoni ) regimens across health care settings has ...


Detailed 48-week results from two large phase 3 clinical trials ( Studies 108 and 110 ) evaluating once-daily Tenofovir alafenamide ( TAF ) 25 mg in treatment-naïve and treatment-experienced adults wi ...


Data has demonstrated that choosing a different combination of direct-acting antiviral ( DAA ) treatment for hepatitis C can eradicate the virus at four weeks in patients who had already failed on pre ...


A pilot study found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a short-duration of six weeks had undetectable HCV after a 12 week follow-up. The ...


New data has confirmed that a novel first-in-class treatment for hepatitis B, called NVR 3-778, is well-tolerated and can reduce levels of the virus’ genetic material in the body when combined with Pe ...


A hepatitis C ( HCV ) drug currently under investigation, ABT-493 and ABT-530, which is an all-oral once-daily antiviral treatment, helped HCV genotype 3 patients with heavily scarred livers and no pr ...


Interim results from one of the ongoing phase II studies of RG-101 for the treatment of hepatitis C virus infection ( HCV ) were announced. The study was designed to evaluate a shortened, 4-week tr ...


A study has evaluated the clinical outcomes of Telaprevir- or Simeprevir-based triple therapy for recurrent hepatitis C after living donor liver transplantation. Twenty-six patients received antiv ...


Six treatment options are available in 2015 for patients infected with HCV genotype 1, including two IFN-containing regimens and four IFN-free regimens. The combination of Sofosbuvir and Ribavirin s ...


All treatment-naïve and –experienced patients with compensated or decompensated chronic liver disease related to ( hepatitis C virus ) HCV, who are willing to be treated and who have no contra-indicat ...


Significant clinical variations exist among patients with hepatocellular carcinoma ( HCC ), the most common type of liver cancer, depending on the viral cause of the disease, hepatitis B virus ( HBV ) ...


Vitamin D receptors ( VDR ) bind calcitriol and modulate several physiological systems through genomic and nongenomic pathways. Calcitriol stimulates store-operated channels Ca influx by translocation ...


Interferon-based treatment is not suitable for many patients with hepatitis C virus ( HCV ) infection because of contraindications such as psychiatric illness, and a high burden of adverse events. L ...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in patients who also have cirrhosis. Researchers have evaluated ...


Glycerol phenylbutyrate ( Ravicti ) lowers ammonia by providing an alternate pathway to urea for waste nitrogen excretion in the form of phenylacetyl glutamine, which is excreted in urine. A rando ...


The first detailed results from pivotal phase III study, PEARL-III, were presented as part of the 21st Conference on Retroviruses and Opportunistic Infections ( CROI ). PEARL-III evaluated the effica ...


Forty percent of patients with autoimmune hepatitis ( AIH ) present with acute jaundice / hepatitis. Such patients, when treated promptly, are thought to have a good prognosis. The objective of a s ...


Entecavir ( Baraclude ) is effective and safe in patients with chronic hepatitis B in the short term, but its long term efficacy and safety has not been established. Researchers have evaluated HBV ...


High rates of sustained virologic response were observed among patients with hepatitis C virus ( HCV ) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor Sofosbuvir ...


The Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ) and the NS5A inhibitor Ombitasvir ( also known as ABT-267 ) plus the nonnucleoside polymerase inhibitor D ...